Our strategy highlights the importance of governance-related topics, which cannot be overstated. Our company’s policies, rules, and procedures define our ability to implement sound strategies that successfully address environmental and social issues.


Our redesigned ESG framework recognizes two distinct forms of issues: Those that relate to our products (what we produce), which are part of the “Product Impact” pillar, and those related to our business operations (how we produce), which are part of the “Operational Impact” pillar. 


Click on the wheel above to learn more about our eight impact-driven strategies

Product impact 

Addressing the social impacts generated by our products is the core of our strategy. These are the areas on which we must focus our resources, to innovate and develop solutions that can contribute to solving some of society’s most pressing challenges. This also represents an opportunity for growth and our strongest competitive advantage. Confronting the health impacts of cigarette smoking is the most important contribution we can make to public health and is the cornerstone of PMI’s purpose and business strategy.

Operational impact 

We must responsibly manage the impacts of our company’s operations throughout the value chain. From a social standpoint, this includes ensuring fair treatment and empowerment of our employees and improving the lives of people across our supply chain. On the environmental front, this means tackling climate change and preserving natural ecosystems.

This online content about our Integrated Report should be read in conjunction with PMI’s Integrated Report 2022. Unless otherwise indicated, the data contained herein cover our operations worldwide for the full calendar year 2022 or reflect the status as of December 31, 2022. Where not specified, data comes from PMI financials, non-financials, or estimates. Unless explicitly stated, the data, information, and aspirations referenced do not incorporate PMI’s Vectura Fertin Pharma business (consolidating the 2021 acquisitions of wellness and healthcare companies Fertin Pharma A/S, Vectura Group plc., and OtiTopic, Inc.), nor the late 2022 acquisition of Swedish Match AB. Please also refer to 'This report at a glance' on page 2 of the Integrated Report 2022 for more information. Aspirational targets and goals do not constitute financial projections, and achievement of future results is subject to risks, uncertainties and inaccurate assumptions, as outlined in our forward-looking and cautionary statements on page 214. In the Integrated Report 2022 and in related communications, the terms “materiality,” “material,” and similar terms, when used in the context of economic, environmental, and social topics, are defined in the referenced sustainability standards and are not meant to correspond to the concept of materiality under the U.S. securities laws and/or disclosures required by the U.S. Securities and Exchange Commission.

Share this page